Please use this identifier to cite or link to this item:
http://hdl.handle.net/10362/143282| Title: | Pfizer after the covid-19: new opportunity or substantial concentration risk |
| Author: | Romão, Tiago Sampaio |
| Advisor: | Martins, Francisco |
| Keywords: | Valuation M&A Finance Technological innovation Covid-19 Pharma Equity research Wacc Pfizer |
| Defense Date: | 7-Jun-2022 |
| Abstract: | The Equity Research report intends to introduce investors with key insights regarding the stock performance and intrinsic value of Pfizer. Covid-19 pandemic brought new opportunities, as well as new challenges and risks that need to be analyzed to provide a conclusion on which effect prevails and outweighs the other. The full spectrum, from industry analysis and trends to peer comparison represent a value-added approach to the company’s specific data. In the end, the valuation suggests a buy recommendation with Pfizer stock being priced at $56.08 per share by 31 December 2022, representing a 16% annualized shareholder return, including capital gains and dividend payment. |
| URI: | http://hdl.handle.net/10362/143282 |
| Designation: | A Work Project, presented as part of the requirements for the Award of a Masters Degree in Finance from the NOVA – School of Business and Economics |
| Appears in Collections: | NSBE: Nova SBE - MA Dissertations |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 29977_david_arias_2020-21_spring_32305_tiago_rom_o_239604_783814904.pdf | 644,95 kB | Adobe PDF | View/Open |
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
